Patents by Inventor H. Shaw Warren

H. Shaw Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
    Publication number: 20160213742
    Abstract: Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a ? 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.
    Type: Application
    Filed: September 4, 2014
    Publication date: July 28, 2016
    Applicants: Cidara Therapeutics, Inc., Cidara Therapeutics, Inc.
    Inventors: Kevin Michael FORREST, James Kevin JUDICE, H. Shaw WARREN, James Michael BALKOVEC, Thomas Patrick BRADY
  • USE OF HEMOPEXIN TO SEQUESTER HEMOGLOBIN
    Publication number: 20140249087
    Abstract: The invention relates to use of hemopexin (Hx) to sequester extravascular hemoglobin and thereby reduce or prevent inflammation of non-infectious etiology in a subject (e.g., a human).
    Type: Application
    Filed: September 27, 2012
    Publication date: September 4, 2014
    Inventor: H. Shaw Warren
  • Inflammation-inhibitory serum factors and uses thereof
    Patent number: 8821851
    Abstract: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: September 2, 2014
    Assignees: The General Hospital Corporation, Institut Pasteur
    Inventors: H. Shaw Warren, Jean-Marc Cavaillon
  • Use of apolipoproteins to decrease inflammation
    Patent number: 8722630
    Abstract: The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory response due to an autoimmune disease or an injury).
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: May 13, 2014
    Assignee: The General Hospital Corporation
    Inventor: H. Shaw Warren
  • USE OF APOLIPOPROTEINS TO DECREASE INFLAMMATION
    Publication number: 20110195893
    Abstract: The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory response due to an autoimmune disease or an injury).
    Type: Application
    Filed: June 15, 2009
    Publication date: August 11, 2011
    Applicant: The General Hospital Corporation
    Inventor: H. Shaw Warren
  • Inflammation-Inhibitory Serum Factors and Uses Thereof
    Publication number: 20090175797
    Abstract: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.
    Type: Application
    Filed: March 22, 2007
    Publication date: July 9, 2009
    Applicant: THE GERNERAL HOSPITAL CORPORATION
    Inventors: H. Shaw Warren, Jean-Marc Cavaillon
  • Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
    Publication number: 20030017162
    Abstract: The present invention relates to three outer membrane proteins conserved among Gram-negative bacteria, OmpA, PAL, and MLP. The invention provides vaccines and polypeptides useful for passive and active immunization against Gram-negative bacteria, as well as methods of preventing and treating Gram-negative sepsis.
    Type: Application
    Filed: March 13, 2002
    Publication date: January 23, 2003
    Inventors: H. Shaw Warren, Judith Hellman, James T. Kurnick